David Moatazedi Sells 6,251 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the sale, the insider now directly owns 508,619 shares of the company’s stock, valued at approximately $6,306,875.60. This trade represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Evolus Stock Down 1.6 %

Evolus stock opened at $12.05 on Friday. The company has a 50 day moving average of $13.66 and a 200-day moving average of $13.79. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a twelve month low of $9.25 and a twelve month high of $17.82. The stock has a market capitalization of $766.22 million, a PE ratio of -13.24 and a beta of 1.28.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Barclays lifted their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, March 5th.

Hedge Funds Weigh In On Evolus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Evolus by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company’s stock worth $347,000 after buying an additional 1,094 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Evolus by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after acquiring an additional 1,291 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Evolus by 2.2% in the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock worth $885,000 after purchasing an additional 1,762 shares in the last quarter. Tradition Wealth Management LLC lifted its position in Evolus by 18.2% during the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its stake in shares of Evolus by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock worth $378,000 after buying an additional 2,044 shares during the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.